PT  - JOURNAL ARTICLE
AU  - Ayya Keshet
AU  - Amir Gavrieli
AU  - Hagai Rossman
AU  - Smadar Shilo
AU  - Tomer Meir
AU  - Tal Karady
AU  - Amit Lavon
AU  - Dmitry Kolobkov
AU  - Iris Kalka
AU  - Saar Shoer
AU  - Anastasia Godneva
AU  - Ori Cohen
AU  - Adam Kariv
AU  - Ori Hoch
AU  - Mushon Zer-Aviv
AU  - Noam Castel
AU  - Anat Ekka Zohar
AU  - Angela Irony
AU  - Benjamin Geiger
AU  - Yuval Dor
AU  - Dorit Hizi
AU  - Ran Balicer
AU  - Varda Shalev
AU  - Eran Segal
TI  - The effect of a national lockdown in response to COVID-19 pandemic on the prevalence of clinical symptoms in the population
AID  - 10.1101/2020.04.27.20076000
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20076000
4099  - http://medrxiv.org/content/early/2020/12/28/2020.04.27.20076000.short
4100  - http://medrxiv.org/content/early/2020/12/28/2020.04.27.20076000.full
AB  - The vast and rapid spread of COVID-19 calls for immediate action from policy-makers, and indeed various lockdown measures were implemented in many countries. Here, we utilized nationwide surveys that assess COVID-19 associated symptoms to analyze the effect of the lockdown policy in Israel on the prevalence of clinical symptoms in the population. Daily symptom surveys were distributed online and included fever, respiratory symptoms, gastrointestinal symptoms, anosmia and Ageusia. A total of 1,456,461 survey responses were analyzed. We defined a single measure of symptoms, Symptoms Average (SA), as the mean number of symptoms reported by responders. Data were collected between March 15th to May 11th, 2020. Notably, following severe lockdown measures, we found that between March 15th and April 20th, SA sharply declined by 83.8%, as did every individual symptom, including the most common symptoms reported by our responders, cough and rhinorrhea and\or nasal congestion, which decreased by 74.1% and 69.6%, respectively. Individual symptoms exhibit differences in reduction dynamics, suggesting differences in the medical conditions that they represent or in the nature of the symptoms themselves. The reduction in symptoms was observed in all the cities in Israel, and in several stratifications of demographic characteristics. Between April 20th and May 11th, following several subsequent lockdown relief measures, the decrease in SA and individual symptoms halted and they remain relatively stable with no significant change. Overall, these results demonstrate a profound decrease in a variety of clinical symptoms following the implementation of a lockdown in Israel. As our survey symptoms are not specific to COVID-19 infection, this effect likely represents an overall nationwide reduction in the prevalence of infectious diseases, including COVID-19. This quantification may be of major interest for COVID-19 pandemic, as many countries consider implementation of lockdown strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board (IRB) of the Weizmann Institute of Science. Informed consent was waived by the IRB, as all identifying details of the participants were removed before the computational analysis. Participants were made fully aware of the way in which the data will be stored, handled and shared, which was provided to them and is in accord with the privacy and data-protection policy of the Weizmann Institute of Science (https://weizmann.ac.il/pages/privacy-policy).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey.https://github.com/hrossman/Covid19-Survey